A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
Status:
Completed
Trial end date:
2019-04-02
Target enrollment:
Participant gender:
Summary
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the
Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin
(rhu-pGSN) Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired
Pneumonia (CAP)